Alvotech Reports Data from the Trial of AVT03 (Biosimilar, Prolia and Xgeva) for Skeletal Diseases
Shots:
- The (AVT03-GL-P01) study assessing safety, PK and tolerability of AVT03 (denosumab) vs Prolia in healthy adult individuals met the 1EPs
- The confirmatory study of AVT03 in patients and a trial to evaluate PK of AVT03 vs Xgeva in healthy adult individuals is ongoing
- AVT03, a mAb, targets RANK ligand to reduce the numbers and function of osteoclast for stopping bone resorption and cancer-induced bone destruction
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Reports the Initiation of Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva to Treat Bone Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
